Get started
Author

Maria E. Grishunina

Observed names: M. E. Grishunina, M.E. Grishunina, Maria E Grishunina, Maria Grishunina
ORCID: 0000-0002-2663-7128
Observed ORCID: 0000-0002-2663-7128
OpenAlex ID: A5080998304
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
2011 · Philippe Moreau, Halyna Pylypenko, et al. · The Lancet Oncology · 930
A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
2010 · Philippe Moreau, Halyna V Pylypenko, et al. · Blood · 13
Comparison of the treatment results in adult patients with acute Ph-negative lymphoblastic leukemia on protocols of the Russian multicenter studies ALL-2009 and ALL-2016
2022 · E. N. Parovichnikova, O. A. Aleshina, et al. · Гематология и трансфузиология · 10
PDF
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease
2023 · Olga A. Aleshina, Kristina Zakurdaeva, et al. · Clinical Lymphoma Myeloma & Leukemia · 9
PDF
Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry
2020 · Olga A. Gavrilina, Kristina Zakurdaeva, et al. · Blood · 4
Treatment outcomes for acute T-lymphoblastic leukemias/lymphomas: data from the ALL-2016 multicenter prospective randomized trial
2023 · O. A. Aleshina, I. V. Galtseva, et al. · Oncohematology · 3
PDF
The use of pegaspargase in adult Ph-negative acute lymphoblastic leukemia patients in the treatment according to the all-2016 protocol
2023 · O. A. Aleshina, E. S. Kotova, et al. · Гематология и трансфузиология · 1
PDF
Final Results of CHRONOS19 Observational Study in Patients with Hematologic Disease and COVID-19 in Russia
2021 · Olga A. Gavrilina, Kristina A. Zakurdaeva, et al. · Blood · 1
Interim Results of Russian Acute Lymphoblastic Leukemia (RALL-2016) Study with Centralized MRD-Monitoring and Randomization for Autologous HSCT with Non-Myeloablative Conditioning in Adult Ph-Negative ALL Patients
2019 · Olga A. Gavrilina, Elena N. Parovichnikova, et al. · Blood · 1
ALL-329 Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescent and Young Adults: Long-Term Outcomes After Treatment According to the Adult Strategy RALL Protocol
2023 · Olga Aleshina, Ekaterina Kotova, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ALL-329 Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescent and Young Adults: Long-Term Outcomes After Treatment According to the Adult Strategy RALL Protocol
2023 · Olga Aleshina, Ekaterina Kotova, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
P396: Fifteen Years of Russian Research in the Treatment of Adult Patients With Acute Ph-negative Lymphoblastic Leukemia According to the Protocols All-2009 and All-2016.
2023 · Olga Aleshina (Gavrilina), Vera Troitskaya, et al. · HemaSphere
Non-Intensive Continuous Treatment with a Tyrosine Kinase Inhibitor (TKI) Followed By Allo-HSCT Is an Effective Therapeutic Strategy for Adult Ph-Positive Acute Lymphoblastic Leukemia: Outcomes of the Russian Prospective Multicenter RALL Study
2021 · Olga A. Gavrilina, Elena N. Parovichnikova, et al. · Blood
1590P Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies
2021 · K. Zakurdaeva, O.A. Gavrilina, et al. · Annals of Oncology
PDF
ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry
2021 · Olga Gavrilina, Kristina Zakurdaeva, et al. · Clinical Lymphoma Myeloma & Leukemia
Poster: ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry
2021 · Olga Gavrilina, Kristina Zakurdaeva, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 16
Citation count: 972
H-index: 4
I10-index: 3
Year
Topic
Type